Kura Oncology, Inc.
General ticker "KURA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $673.9M (TTM average)
Kura Oncology, Inc. follows the US Stock Market performance with the rate: 51.4%.
Estimated limits based on current volatility of 2.7%: low 8.72$, high 9.20$
Factors to consider:
- Total employees count: 192 (+35.2%) as of 2024
- Top business risk factors: Dependence on lead product, Limited operating history, Third-party risks, Cybersecurity threats, Strategic risks and growth management
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.80$, 13.31$]
- 2025-12-31 to 2026-12-31 estimated range: [3.58$, 9.80$]
Financial Metrics affecting the KURA estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: Operating cash flow per share per price, % of 17.59 > 12.91
- Positive: Interest expense per share per price, % of 0.21 <= 0.74
- Positive: 42.53 < Shareholder equity ratio, % of 54.41 <= 64.17
- Positive: -14.19 < Investing cash flow per share per price, % of -13.30
- Negative: negative Industry operating cash flow (median)
Short-term KURA quotes
Long-term KURA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $53.88MM |
| Operating Expenses | $139.87MM | $165.80MM | $247.08MM |
| Operating Income | $-139.87MM | $-165.80MM | $-193.19MM |
| Non-Operating Income | $4.03MM | $13.17MM | $21.23MM |
| Interest Expense | $0.23MM | $1.55MM | $1.62MM |
| R&D Expense | $92.81MM | $115.23MM | $169.97MM |
| Income(Loss) | $-135.84MM | $-152.63MM | $-171.97MM |
| Taxes | $0.00MM | $0.00MM | $2.02MM |
| Profit(Loss)* | $-135.84MM | $-152.63MM | $-173.98MM |
| Stockholders Equity | $420.28MM | $397.27MM | $413.64MM |
| Assets | $456.31MM | $448.94MM | $760.16MM |
| Operating Cash Flow | $-110.06MM | $-124.82MM | $134.32MM |
| Capital expenditure | $0.63MM | $0.17MM | $0.47MM |
| Investing Cash Flow | $32.63MM | $15.56MM | $-101.59MM |
| Financing Cash Flow | $38.56MM | $94.78MM | $154.42MM |
| Earnings Per Share** | $-2.03 | $-2.08 | $-2.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.